Prognostic implications of left ventricular wall motion abnormalities associated with subarachnoid hemorrhage.

Management of aneurysmal subarachnoid hemorrhage. Crit Care Med (2009) 1.76

Incidence and outcome of cardiac injury in patients with severe head trauma. Scand J Trauma Resusc Emerg Med (2016) 1.40

Elevated cardiac troponin I and relationship to persistence of electrocardiographic and echocardiographic abnormalities after aneurysmal subarachnoid hemorrhage. Stroke (2009) 1.18

Prevalence of transthoracic echocardiographic abnormalities in patients with ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. Arch Med Sci (2010) 1.07

Automatic classification of left ventricular regional wall motion abnormalities in echocardiography images using nonrigid image registration. J Digit Imaging (2013) 0.93

Cardiac manifestations of subarachnoid hemorrhage. Heart Lung Vessel (2013) 0.93

Association between elevated plasma norepinephrine levels and cardiac wall motion abnormality in poor-grade subarachnoid hemorrhage patients. Neurosurg Rev (2012) 0.85

Long-Term Outcomes for Different Forms of Stress Cardiomyopathy After Surgical Treatment for Subarachnoid Hemorrhage. Anesth Analg (2016) 0.75

Elevated high-sensitive troponin T on admission is an indicator of poor long-term outcome in patients with subarachnoid haemorrhage: a prospective observational study. Crit Care (2016) 0.75

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet (2007) 9.56

Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol (2009) 5.70

Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J Am Coll Cardiol (2007) 2.97

A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood (2005) 2.90

Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. Circulation (2009) 2.83

Takotsubo cardiomyopathy with involvement of delayed-onset rhabdomyolysis and acute kidney injury after rosuvastatin treatment. Intern Med (2015) 2.64

Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem (2007) 2.44

Multifunctional Alloys Obtained via a Dislocation-Free Plastic Deformation Mechanism. Science (2003) 2.33

OCT-based diagnosis and management of STEMI associated with intact fibrous cap. JACC Cardiovasc Imaging (2013) 2.31

Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol (2002) 2.26

The C-type lectin receptors CLEC-2 and Dectin-1, but not DC-SIGN, signal via a novel YXXL-dependent signaling cascade. J Biol Chem (2007) 2.24

Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J (2009) 2.23

Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circ J (2010) 2.13

Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol (2009) 2.08

Myocardial velocity gradient as a noninvasively determined index of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2003) 2.05

Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J (2009) 2.01

Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem (2010) 1.77

Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. JACC Cardiovasc Imaging (2012) 1.77

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother (2010) 1.70

Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res (2005) 1.65

Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci (2007) 1.64

Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace (2010) 1.63

siRNA-based therapy ameliorates glomerulonephritis. J Am Soc Nephrol (2010) 1.58

Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial). Circ J (2010) 1.58

Three or more median sternotomies for patients with valve disease: role of computed tomography. Ann Thorac Surg (2003) 1.58

Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol (2004) 1.55

Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer (2002) 1.54

Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist. Biochem Biophys Res Commun (2002) 1.53

Impact of sirolimus-eluting stent fracture on 4-year clinical outcomes. Circ Cardiovasc Interv (2011) 1.51

Circulating high-mobility group box 1 and cardiovascular mortality in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis (2012) 1.51

Prevalence and clinical implication of metabolic syndrome in chronic heart failure. Circ J (2010) 1.51

Does intensive management of cerebral hemodynamics and atheromatous aorta reduce stroke after coronary artery surgery? Ann Thorac Surg (2008) 1.50

Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc Res (2003) 1.46

Prognostic significance of circadian variability of RR and QT intervals and QT dynamicity in patients with chronic heart failure. Heart Rhythm (2007) 1.45

Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry. Circ J (2013) 1.45

Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy--the extended JAPAN-ACS study. Circ J (2012) 1.45

Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertens Res (2010) 1.44

Use of a whole blood rapid panel test for heart-type fatty acid-binding protein in patients with acute chest pain: comparison with rapid troponin T and myoglobin tests. Am J Med (2003) 1.44

Non-Gaussian heart rate as an independent predictor of mortality in patients with chronic heart failure. Heart Rhythm (2007) 1.44

Lower serum level of adiponectin is associated with increased risk of endoscopic erosive gastritis. Dig Dis Sci (2011) 1.43

Morphologic and functional assessment of coronary artery disease--potential application of computed tomography angiography and myocardial perfusion imaging. Circ J (2012) 1.41

Multimarker approach to risk stratification for long-term mortality in patients on chronic hemodialysis. Circ J (2015) 1.41

High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol (2005) 1.41

Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome: the JAPAN-ACS subanalysis study. Circ J (2012) 1.40

Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures. Eur Heart J (2012) 1.38

Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis (2008) 1.37

National survey of fulminant myocarditis in Japan: therapeutic guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a scientific committee). Circ J (2002) 1.36

Neuroprotective effect of exogenous microglia in global brain ischemia. J Cereb Blood Flow Metab (2006) 1.35

Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome. Circ Arrhythm Electrophysiol (2009) 1.33

Renal contraction therapy for enlarged polycystic kidneys by transcatheter arterial embolization in hemodialysis patients. Am J Kidney Dis (2002) 1.32

Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate (2003) 1.32

Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation (2014) 1.30

Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke (2008) 1.29

Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis (2009) 1.28

Function and role of microparticles in various clinical settings. Thromb Res (2008) 1.28

Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis (2009) 1.25

Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol (2010) 1.23

Platelet activation receptor CLEC-2 regulates blood/lymphatic vessel separation by inhibiting proliferation, migration, and tube formation of lymphatic endothelial cells. J Biol Chem (2012) 1.20

Laminin stimulates spreading of platelets through integrin alpha6beta1-dependent activation of GPVI. Blood (2005) 1.19

Sphingosine 1-phosphate-related metabolism in the blood vessel. J Biochem (2005) 1.18

Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography. Circulation (2004) 1.18

Plasma sphingosine-1-phosphate measurement in healthy subjects: close correlation with red blood cell parameters. Ann Clin Biochem (2008) 1.17

Personalized peptide vaccine for treatment of advanced cancer. Curr Med Chem (2014) 1.17

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer (2008) 1.16

Atherosclerotic plaque characterization by 0.5-mm-slice multislice computed tomographic imaging. Circ J (2007) 1.15

Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol (2002) 1.15

Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci (2006) 1.14

New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg (2002) 1.12

Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size. J Immunol (2002) 1.12

Serial coronary CT angiography-verified changes in plaque characteristics as an end point: evaluation of effect of statin intervention. JACC Cardiovasc Imaging (2010) 1.12

Prognostic value of serum concentration of heart-type fatty acid-binding protein relative to cardiac troponin T on admission in the early hours of acute coronary syndrome. Clin Chem (2005) 1.11

Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds. Microbiol Immunol (2008) 1.11

Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb (2010) 1.11

Interaction between von Willebrand factor and glycoprotein Ib activates Src kinase in human platelets: role of phosphoinositide 3-kinase. Blood (2002) 1.09

Involvement of Src kinases and PLCgamma2 in clot retraction. Thromb Res (2006) 1.09

Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem (2010) 1.09

Expression of the LIM proteins paxillin and Hic-5 in human tissues. J Histochem Cytochem (2003) 1.08

CT angiography with electrocardiographically gated reconstruction for visualizing pulsation of intracranial aneurysms: identification of aneurysmal protuberance presumably associated with wall thinning. AJNR Am J Neuroradiol (2005) 1.08

Restenosis and stent fracture following sirolimus-eluting stent (SES) implantation. Circ J (2007) 1.08

A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep (2010) 1.07

Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol (2008) 1.06

Radial volumetric imaging breath-hold examination (VIBE) with k-space weighted image contrast (KWIC) for dynamic gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI of the liver: advantages over Cartesian VIBE in the arterial phase. Eur Radiol (2014) 1.06

Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res (2004) 1.05

Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther (2010) 1.04

Role of myocardial interstitial edema in conduction disturbances in acute myocarditis. Heart Vessels (2006) 1.04

Cystatin C in acute heart failure without advanced renal impairment. Am J Med (2009) 1.03

Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Int J Oncol (2012) 1.03

Autoantibodies against carbonic anhydrase II are increased in renal tubular acidosis associated with Sjogren syndrome. Am J Med (2005) 1.03

Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol (2006) 1.02

Global trend in overweight and obesity and its association with cardiovascular disease incidence. Circ J (2014) 1.02

Screening for obstructive sleep apnea by cyclic variation of heart rate. Circ Arrhythm Electrophysiol (2010) 1.02

Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother (2009) 1.02

Liver regeneration in heparin-binding EGF-like growth factor transgenic mice after partial hepatectomy. Gastroenterology (2003) 1.01